Latest News and Events
Filter by
Selections
January 24, 2022
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
Read MoreJanuary 12, 2022
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Read MoreDecember 20, 2021
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
Read MoreDecember 17, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreNovember 30, 2021